<DOC>
	<DOCNO>NCT01713478</DOCNO>
	<brief_summary>The prevalence hepatic cirrhosis Romania high , 10-year mortality 34-66 % . Upward trend mortality observe . It known cirrhosis associate cardiac abnormality . These induce several complication cirrhosis , increase postoperative mortality . Therefore , major public health issue research field priority . Few study evaluate cardiac function cirrhotic patient , use conventional echocardiography . However , allow late diagnosis cardiac dysfunction , might already irreversible . Consequently , description new parameter , could detect early dysfunction , become essential . There study design estimate intrinsic myocardial property cirrhosis . New method ( Tissue Doppler Speckle-tracking echocardiography ) could essential detect early cardiac dysfunction . The exact role biological marker diagnosis cardiac dysfunction remain clarified . Impaired cardiac function couple augmented vascular function could model cirrhotic patient . This type ventriculo-arterial interaction never describe . The main objective project : 1. investigate mechanism lead cardiac dysfunction ; 2. describe new parameter early diagnosis cirrhotic cardiomyopathy ; 3. describe type ventriculo-arterial interaction ; 4. association biological marker echo parameter .</brief_summary>
	<brief_title>Subclinical Myocardial Dysfunction Patients With Hepatic Cirrhosis</brief_title>
	<detailed_description>Scientific context motivation : Cirrhosis end stage chronic damage liver . The prevalence estimate high Romania , 1000/100.000 inhabitant , 10-year mortality 34-66 % . Upward trend mortality observed country , include Romania , extremely high mortality rate . The cost term hospital cost lose productivity high . Therefore , hepatic cirrhosis represent major public health Romania . It known hepatic cirrhosis associate cardiovascular abnormality . These abnormality suggest induce/aggravate several complication cirrhosis , also increase postoperative mortality major surgery liver transplantation . Few study document existence hyperdynamic circulation , increase cardiac output reduce systemic vascular resistance . Despite hyperkinetic circulation , patient abnormal ventricular function unmask physiologic/pharmacologic stress . There study cardiac function cirrhosis , although contractile function disorder find nonalcoholic cirrhosis animal model suggest independent alcohol intake . These issue complicate fact , alcohol use represent one commonest cause cirrhosis cardiomyopathy . There reason believe cirrhosis per se may associate subtle contractile dysfunction . First , hyperkinetic circulatory change may induce high-output cardiac failure resemble chronic volume overload heart . Second , cirrhosis associate high serum catecholamine level , long-term exposure elevate catecholamine result cardiomyopathy . Third , necropsy series patient alcoholic/nonalcoholic cirrhosis show similar cardiac pathologic finding : diffuse fibrosis , subendocardial edema , nuclear cytoplasmic vacuolation . Despite increased cardiac output , ventricular inotropic chronotropic response stimuli blunt , condition know `` cirrhotic cardiomyopathy '' . These include systolic diastolic dysfunction , electrophysiological change , structural change . There clear consensus definition condition . Cardiac function evaluate classic echocardiography , 2D color/spectral Doppler : cardiac dimension , leave ventricular ejection fraction ( LVEF ) , systolic diastolic timing . All change dependent load condition , cirrhosis major variability preload condition . However , conventional measurement allow late diagnosis cardiac dysfunction , might already irreversible . Moreover , cardiac dysfunction frequently subclinical appear early stage ( even chronic hepatitis ) . Consequently , early diagnosis subclinical cardiac dysfunction essential management patient . There study design estimate intrinsic myocardial property cirrhosis . Tissue Doppler Imaging ( TDI ) speckle-tracking echocardiography ( STE ) could useful field , major point project . In cirrhosis , different humoral substance enter directly systemic circulation . The following factor involve possible mediator cardiac dysfunction vascular change : increase NO CO production , endocannabinoids , TNF-α , IL-1 , IL-6 . Increased NO production major factor involve peripheral arterial vasodilation cirrhosis . In conclusion , impaired cardiac function couple augmented vascular function could model cirrhotic patient . This type ventriculo-arterial interaction never describe . This could second important point research . Unresolved question : Consensus definition criterion , specific diagnostic test , exact prevalence syndrome , appropriate management strategy unresolved question . To date , single diagnostic test identify cirrhotic patient cardiac dysfunction . Level natriuretic peptide ( proBNP ) elevate due increase cardiac release impair hepatic extraction . Similarly , troponin I report elevate . The exact role marker diagnosis cirrhotic cardiomyopathy , remain clarified . We intend analyze marker , order describe existence pro-inflammatory status , impairment oxidative stress presence myocardial fibrosis . The association marker different parameter cardiac dysfunction also describe study , first time . The optimum management cirrhotic cardiomyopathy establish since neither `` gold standard '' diagnostic criterion specific treatment present . We consider research could make progress field . Objectives . The main objective detect , new echocardiographic method , early cardiac dysfunction cirrhotic patient , establish usefulness different biomarkers diagnosis condition . This information couple data regard endothelial function , order describe new type ventriculo-arterial interaction ( intrinsic myocardial dysfunction - augment vascular function ) . Main objective : 1. create gold standard protocol early diagnosis cardiac dysfunction , use new echocardiographic method , therefore identify cirrhotic patient risk develop heart failure ; 2. compare effect alcoholic vs. nonalcoholic cirrhosis cardiac vascular function ; 3. ass chronology cardiac abnormality ; 4. define type ventriculo-arterial interaction patient ; 5. analyze different mechanism involve cardiac dysfunction , biological marker ( brain natriuretic peptide , troponins , marker inflammation , cardiac fibrosis , oxidative stress ) ; 6. correlate severity hepatic disease ( Child-Pugh score ) different parameter cardiac dysfunction biological marker ; 7. test implication genetic disorder occurrence cardiac dysfunction patient ; 8. generate new research , use stress echocardiography cirrhotic patient order find stress-induced subtle cardiac dysfunction , absent rest ; 9. create new opportunity research management strategy cirrhotic patient secondary cardiac dysfunction . Methods . All patient normal individual assess : 1 . General data : age , sex , IMC , blood pressure , heart rate , cardiac risk factor , clinical stage cirrhosis , Child-Pugh score , date diagnosis complication , previous investigation . 2 . Electrocardiogram ( 12 lead ) routine blood sample . 3 . Specific biomarkers : proBNP , troponin , myocardial fibrosis ( β cross lap procollagen type-1 amino terminal ) , marker inflammation ( PCR-hs , IL1 , IL6 , IL 10 , TNFα ) ; oxidative stress : carbonyl plasmatic protein , antioxidant capacity plasma . 4 . Comprehensive Echocardiography : VIVID 9 GE echo machine , dedicate software ECHOPAC BT11 : Conventional echocardiography : - Structural parameter : thickness cardiac wall ; diameter volumes cardiac cavity , aorta , pulmonary artery ; left ventricular ( LV ) mass ; wall stress . - Functional parameter systolic diastolic function : LVEF , LV shorten fraction , left/right cardiac output index , tricuspid mitral annular excursion ; parameter derive transmitral , transtricuspid , aortic pulmonary flow , different systolic/diastolic timing ratio ( LV/RV TEI index , pre-ejection/ejection ratio , etc ) . - Q analysis TDI : measurement isovolumic acceleration , systolic diastolic myocardial velocity derive time , strain level basal mid , LV/RV myocardial segment . - STE - This method offer alternative technique TDI ( angle dependent ! ! ) myocardial deformation ( measure strain strain rate ) radial , longitudinal , circumferential direction , order ass LV/RV systolic diastolic function , LV torsion , leave right atrial function . - 3D echocardiography - precise evaluation cardiac chamber anatomy volume . 4D analysis enables post-processing multi-plane imaging datasets , allow multidimensional imaging acquire parasternal bi-plane apical tri-plane view , support 2D , color , well , tissue Doppler mode ( include tissue synchronization image ) . 5 . Measurement endothelial function , parameter arterial remodeling , arterial stiffness level common carotid artery ( vascular remodel arterial stiffness index ) , level brachial artery ( endothelial function ) . Assessment do use ALOKA α10 ultrasound machine , equip `` echo-tracking '' system . Meanwhile , dedicate new software ( wave intensity analysis ) use assess ventriculo-arterial coupling . Another system ( Complior ) use order measure pulse wave velocity 2 arterial site ( carotid-femoral carotid-radial ) , measure arterial stiffness . The relevance proposal : Investigators know hepatic cirrhosis represent major public health Romania . Because cardiac dysfunction induces/aggravates several complication cirrhosis , lead significant increase morbidity , mortality , economical cost . Thus , creation gold standard protocol detection early cardiac dysfunction , investigator able identify cirrhotic patient risk develop heart failure . Investigators believe early identification cardiac dysfunction health problem major interest . New imagistic laboratory parameter might essential identify patient risk find treatment strategy patient . This could generate new research project treatment field , untouched field . Our proposal create knowledge medical field generate important scientific result , nationally internationally competitive . It could define mechanisms cardiac dysfunction induce cirrhosis , describe new type arterial-ventriculo interaction . Moreover , might able introduce clinical practice `` gold standard '' evaluation patient risk develop cardiac dysfunction , consequently lead optimization therapy . Therefore , result project could applicative also social economic purpose .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Patients certify diagnosis hepatic cirrhosis ; Age 18 year ; Informed consent sign ; Sinus rhythm ; Ejection fraction &gt; 50 % Any history cardiovascular disease/active cardiovascular treatment ( βblockers use prevention variceal hemorrhage stop 24h evaluation ) ; Diabetes mellitus ; Chronic diseases/neoplasia estimate survival time 6 month ; Pulmonary disease could affect cardiac function ; Other etiology cirrhosis could affect cardiac function : Wilson disease , hemochromatosis , glycogen storage disease ; Encephalopathy grade 2/ascitis without medical control ; Inappropriate quality echocardiographic image .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>hepatic cirrhosis</keyword>
	<keyword>subclinical myocardial dysfunction</keyword>
	<keyword>echocardiography</keyword>
	<keyword>specific biomarkers</keyword>
	<keyword>vascular assessment</keyword>
</DOC>